Showing 3001-3010 of 5771 results for "".
- BlueRock Receives FDA Clearance for IND Application of OpCT-001 for Primary Photoreceptor Diseaseshttps://modernod.com/news/bluerock-therapeutics-receives-fda-clearance-for-ind-application-of-opct-001-for-primary-photoreceptor-diseases/2482422/Bayer subsidiary BlueRock Therapeutics announced that the FDA has cleared its investigational new drug (IND) application for OpCT-001, an investigational induced pluripotent stem cell (iPSC)-derived therapy designed to treat primary photoreceptor diseases. The clearance allows BlueRock to in
- Samsara Vision Promotes Jason Herod to Chief Commercial Officerhttps://modernod.com/news/samsara-vision-promotes-jason-herod-to-chief-commercial-officer/2482421/Samsara Vision announced that Jason Herod, formerly Vice President Commercial, International Markets, has been promoted to Chief Commercial Officer (CCO), effective August 15, 2024. Mr. Herod joined Samsara Vision in August 2021, bringing with him over 24 years of extensive experi
- SIFI Receives European Commission Approval for Akantiorhttps://modernod.com/news/avanzanite-bioscience-secures-european-commission-approval-for-akantior-first-treatment-for-acanthamoeba-keratitis/2482417/SIFI announced the European Commission has approved Akantior (polihexanide) for the treatment of acanthamoeba keratitis (AK) in adults and children from 12 years of age. Akantior is the first and only approved therapy for people suffering from AK in Europe. AK is an ultr
- Oculus Debuts Dual Testing Functionality on Easyfield VR for Enhanced Visual Field Assessmenthttps://modernod.com/news/oculus-debuts-dual-testing-functionality-on-easyfield-vr-for-enhanced-visual-field-assessment/2482416/Oculus has announced the debut of dual testing functionality on its Oculus Easyfield VR, which allows for both Frequency Doubling Perimetry (FDP) and Standard Automated Perimetry (SAP). The integration of Frequency Doubling Perimetry into the Easyfield VR allows for the potent
- Injectsense Completes First Successful Human Implant of Ultraminiature Intraocular Pressure Sensorhttps://modernod.com/news/injectsense-completes-first-successful-human-implant-of-ultraminiature-intraocular-pressure-sensor/2482413/Injectsense has announced the completion of the first human implant and subsequent wireless IOP measurements using its ultraminiature implantable sensor, which has received FDA breakthrough designation. The IOP-Connect system study is being conducted under the leadership
- Rayner Launches First AI-Designed Spiral IOL, the RayOne Galaxyhttps://modernod.com/news/rayner-announces-launch-of-rayone-galaxy-first-ai-designed-spiral-iol/2482411/Rayner announced its plans to launch the RayOne Galaxy and Galaxy Toric, which the company is calling the world’s first IOL designed with the aid of artificial intelligence. The IOLs will be unveiled at the European Society of Cataract and Refractive Surgeons (
- Ocugen Receives Health Canada Approval to Initiate Phase 3 Clinical Trial for Retinitis Pigmentosahttps://modernod.com/news/ocugen-receives-health-canada-approval-to-initiate-phase-3-clinical-trial-for-retinitis-pigmentosa/2482410/Ocugen announced that Health Canada has provided a “No Objection Letter” to initiate the phase 3 Limelight clinical trial for OCU400 in Canada. OCU400 is a modifier gene therapy product candidate designed for the treatment of retinitis pigmentosa (RP). "Expand
- Visionix Unveils the VX 610 Automated Fundus Camerahttps://modernod.com/news/visionix-unveils-the-vx-610-automated-fundus-camera/2482407/Visionix USA announced the launch of the VX 610 non-mydriatic automated fundus camera. The VX 610 boasts a range of automated features, including auto alignment, auto focus, and auto capture. This level of automation not only streamlines the imaging process but also redu
- Opus Genetics Receives FDA Rare Pediatric Disease Designation for Gene Therapy OPGx-LCA5https://modernod.com/news/opus-genetics-receives-fda-rare-pediatric-disease-designation-for-gene-therapy-opgx-lca5/2482403/Opus Genetics announced that the FDA has granted rare pediatric disease (RPD) designation for its ocular gene therapy, OPGx-LCA5. This therapy is designed to treat patients with Leber congenital amaurosis (LCA) type 5, a rare inherited retinal disease caused by biallelic mutations in th
- Ocuvex Therapeutics Acquires Visiox Pharmaceuticalshttps://modernod.com/news/visiox-pharmaceuticals-merges-with-ocuvex-therapeutics/2482402/Early-stage ophthalmic biotech company Ocuvex Therapeutics announced an agreement to acquire Visiox Pharmaceuticals. Terms of the deal were not disclosed. Visiox's lead asset is Omlonti (omidenepag isopropyl ophthalmic solution 0.002%), an EP2 rece